VJOncology is committed to improving our service to you

BTOG 2017 | How to discuss immunotherapy as a treatment option with lung cancer patients

VJOncology is committed to improving our service to you

Rolf Stahel

Rolf A. Stahel, MD, University Hospital Zürich, Zürich, Switzerland, provides advice on how to discuss immunotherapy as a second-line treatment option for patients with lung cancer. He highlights that approximately 1in 6 to 1 in 5 patients benefit from the treatment and that this should be clearly communicated to patients.

Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter